A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
A phase 1/2 trial of Daratumumab, Dexamethasone, Pomalidomide in multiple myeloma, run by AbbVie, now recruiting.
Overview
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06953960 by AbbVie, with 325 participants planned, started 2025-07-23 and due to reach its primary completion in 2030-12. Interventions recorded: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Pomalidomide, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.